Summer Sale
50% off Premium Yearly
Opinions Andrey Omelchak
Knight TherapeuticsGUD.TOCOMMENTFeb 24, 2017
Andrey OmelchakStock price when the opinion was issued
As of Jun 19, 2026. Market Open.
You might be interested:
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free
Stockchase Insights
James Hodgins
Ryan ModestoHis biggest holding. They have $6.85 in tangible book value, mostly cash. The CEO may buy Paladin or Cipher Pharmaceuticals. Be patient for this deal. It'll be accretive.
James Hodgins
Over the long-term, you can’t go wrong with this. You are paying premium for their BV at this point. It has a lot of cash with a limited amount of businesses that are generating free cash flow at this time. It is run by the best management team in the country. They are patient and have done this in the past. This is going to be the company that picks up good things when things blow up. They are planting a lot of seeds that one day will pay off in dividends.